Results 81 to 90 of about 41,400 (225)

Inflammatory Scores: Comparison and Utility in HCC Patients Undergoing Transarterial Chemoembolization in a North American Cohort

Journal of Hepatocellular Carcinoma, 2021
Shamar Young,1 Isa Cam,1 Mehmet Gencturk,1 Nathan Rubin,2 Donna D’souza,1 Siobhan Flanagan,1 Jafar Golzarian,1 Tina Sanghvi3 1University of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA ...
Young S, Cam I, Gencturk M, Rubin N, D'souza D, Flanagan S, Golzarian J, Sanghvi T   +7 more
doaj  

Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation [PDF]

, 2005
Aim: To evaluate the outcome of transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) 3 cm in diameter were adverse prognostic factors in multivariate analysis.
Fan, ST, Liem, MSL, Lo, CM, Poon, RTP, Tso, WK   +4 more
core   +1 more source

Establishment and Comparative Analysis of Radiation‐Induced Liver Disease in Normal and Fibrotic Rat Models

Precision Radiation Oncology, EarlyView.
This study successfully established two novel rat models of radiation‐induced liver disease (RILD), one in healthy livers and the other in TAA‐induced fibrotic livers, providing valuable insights into the combined effects of radiation and pre‐existing fibrosis.
Yanting Jiang, Yuxi Ding, Fang Wang, Danni Chen, Weixiang Zhong, Zhongjie Lu, Yixiang J. Wang, Senxiang Yan, Xiaoguang Liu, Feng Zhao   +9 more
wiley   +1 more source

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib [PDF]

, 2016
ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC.
Abbadessa, Giovanni, Borbath, Ivan, Daniele, Bruno, De Toni, Enrico N, Gasbarrini, Antonio, Lamar, Maria E, Lencioni, Monica, Miles, Steven, Personeni, Nicola, Porta, Camillo, Rimassa, Lorenza, Salvagni, Stefania, Santoro, Armando, Schwartz, Brian E, Shuster, Dale, Trojan, Jörg, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Wang, Yunxia, Weiss, Alan   +19 more
core   +4 more sources

Oxygen‐independent expression of HIF‐1α during the cell cycle in hepatocellular carcinoma cells controls essential metabolic pathways under normoxia

The FEBS Journal, EarlyView.
In Huh7 cells, HIF‐1α is essential as it maintains the expression of proteins involved in glycolysis and steroid/cholesterol biosynthesis both under normoxia and hypoxia. On the other hand, in HeLa cells, these pathways are induced by HIF‐1α only under hypoxia.
Ioanna‐Maria Gkotinakou, Christina Arseni, Kreon Koukoulas, Martina Samiotaki, George Panayotou, George Simos, Ilias Mylonis   +6 more
wiley   +1 more source

Comparative Evaluation of Intraarterial Therapy Methods for Hepatocellular Cancer

Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Aim: to compare various methods of intraarterial therapy for hepatocellular carcinoma (HCC) in terms of survival, adverse events, and cost-effectiveness.Key points.
A. P. Petrosyan, V. V. Kucherov, Yu. A. Emelyanova, A. D. Kaprin, S. A. Ivanov, L. O. Petrov, N. A. Falaleeva, A. G. Isaeva, A. S. Dikova, A. T. Stekhova, E. A. Volicheva   +10 more
doaj   +1 more source

Combined transarterial chemoembolization and arterial administration of Bletilla striata in treatment of liver tumor in rats [PDF]

, 2013
AIM: To evaluate and compare the effect of combined transarterial chemoembolization (TACE) and arterial administration of Bletilla striata (a Chinese traditional medicine against liver tumor) versus TACE alone for the treatment of hepatocellular ...
Bechstein, Wolf Otto, Feng, Gan-Sheng, Li, Wei-Yong, Oppermann, Elsie, Qian, Jun, Vogl, Thomas J., Vossoughi, Daryusch, Woitaschek, Dirk   +7 more
core  

Rethinking the role of HIF in hepatocellular carcinoma

The FEBS Journal, EarlyView.
Tumor hypoxia is a hallmark of cancer driving disease, in part through activation of hypoxia‐inducible factors (HIFs). While HIF‐1α is classically understood as a hypoxia‐responsive transcription factor, its role under normoxic conditions in cells is less clear.
Niall S. Kenneth, Michael Batie, Sonia Rocha   +2 more
wiley   +1 more source

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis

Hepatology Research, EarlyView.
The platelet count can be used to predict liver function at the time of evaluation of progressive disease (PD) after atezolizumab plus bevacizumab (ATZ/BEV) therapy in patients with u‐HCC. Treatment strategies in u‐HCC patients with low platelet counts should be conducted by taking into account deterioration of liver function after ATZ/BEV.
Ryo Sato, Takanori Suzuki, Kentaro Matsuura, Daisuke Kato, Katsumi Hayashi, Kohei Okayama, Fumihiro Okumura, Satoshi Sobue, Atsunori Kusakabe, Izumi Hasegawa, Kiyoto Narita, Tsutomu Mizoshita, Yoshihide Kimura, Hiromu Kondo, Hisayo Kojima, Kazuki Hayashi, Atsushi Ozasa, Hayato Kawamura, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Sakurayama Liver Study Group (SLSG)   +21 more
wiley   +1 more source

DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study

Gut and Liver, 2013
Background/AimsTo determine if hepatocellular carcinoma refractory to conventional transarterial chemoembolization (TACE) responds to TACE with DC beads.Methods : Between July 2008 to June 2010, 435 patients underwent TACE.
doaj   +1 more source